Table 2.
Tumour suppressor miRs are identified in PDAC.
| miRs | Expression in PDAC | Clinical Values | Biological processes involved | Detected | Biology Tested | Control | Number of patients | Group Tested | References |
|---|---|---|---|---|---|---|---|---|---|
| miR-148a | Down | D, P, T | Cell proliferation, invasion, migration | Plasma, Tissue | Patients | Matched Adjacent non-cancerous tissues | 65 | PDAC patients with surgical resection | [45,50,76,77] |
| miR-148b | Down | D, T | Cell proliferation, invasion, migration, inhibition of chemo-sensitization | Plasma, Tissue | Patients | Matched Adjacent non-cancerous tissues | 65 | PDAC patients with surgical resection | [45,78] |
| miR-375 | Down | D, P | Tumour growth and apoptosis | Plasma, Tissue | Patients | Matched Adjacent non-cancerous tissues | 65 | PDAC patients with surgical resection | [45,49] |
| miR-125a-3p | Down | D, T, P | Cell proliferation and migration, chemosensitivity, EMT | Blood | Patients, Panc-1, BxPC3, AsPC-1, Capan-2, MIA-PaCa-2 cell lines | Adjacent non-cancerous tissues | 421 | Advanced PDAC cases | [69,70,79] |
| miR-450 | Down | D | Cell differentiation, proliferation, migration and invasion | Panc-1, BxPC3, AsPC-1, Capan-2, MIA-PaCa-2 cell lines | 15 PDAC cell lines | Primary tumours | [63] | ||
| miR-1280 | Down | D, P | Tumour growth | Blood | Patients | 27 Healthy controls | 49 | Stages I, II, III, IV | [47] |
| miR-492 | Down | D, P | Tumour growth and stage | Blood | Patients | 27 Healthy controls | 49 | Stages I, II, III, IV | [47] |
| miR-595 | Down | D, P | Migration, metastasis | Blood | Patients | 27 Healthy controls | 49 | Stages I, II, III, IV | [47] |
| miR-663a | Down | D, P | Tumour growth and stage | Blood | Patients | 27 Healthy controls | 49 | Stages I, II, III, IV | [47] |
| miR-216 | Down | D, T | Increase cell proliferation, invasion | Tissue | Patients, +3 Cell Lines | Normal Pancreatic tissue | 10 | Stage III, IV | [49,80] |
| miR-217 | Down | D, T | Increase cell proliferation, migration, invasion, DNA damage, stress responses, genome stability and cell survival | Tissue | Patients, +3 Cell Lines | Normal Pancreatic tissue | 10 | Stage III, IV | [49,80] |
| miR-130b | Down | D, P, T | Cell proliferation, invasion | Tissue | Patients, Panc-1, BxPC3, AsPC-1, SW1990, MIA-PaCa-2 cell lines | Matched Normal Pancreatic tissue | 52 | Stage I, II III, IV | [75] |
| miR-187 | Down | D, P | Invasion, migration | Tissue | Patients | Normal Pancreatic tissue | 170 | Stages IA, IB, IIA, IIB | [76] |
| let-7 | Down | D, P, T | EMT, invasion | Tissue | Patients | Normal Pancreatic tissue | 170 | Stages IA, IB, IIA, IIB | [76] |
| miR-205 | Down | D, T | Chemoresistance | Pancreatic Juice | Patients | 19 Non-healthy (NPNH) controls | 50 | Advanced PDAC cases | [50,79,81,82] |
| miR-126 | Down | D, P | Cell proliferation, migration, invasion | Tissue | Patients | Normal Pancreatic tissue | 455 | Stages O, I, II, III, IV | [36] |
| miR-20a | Down | D, P | Proliferation, invasion | Blood-plasma | Patients | Healthy individuals | 197 | Stages I, II, III, IV | [35,37,58] |
| miR-144–3p | Down | D, P | Cell cycle arrest, migration, invasion, metastasis, cell proliferation | Tissue | Patients + Panc-1 cell line | Paired adjacent non-tumour tissues | 10 | Stages IA, IB, II, III | [83] |
D: diagnostic biomarker, P: prognostic biomarker, T: therapeutic target.